UPDATE: Maxim Group Upgrades SELLAS Life Sciences Group (SLS) to Buy

(updated to add analsyt comments)

Maxim Group upgraded SELLAS Life Sciences Group (NASDAQ: SLS) from Hold to Buy with a price target of $13.00.

Analyst Jason McCarthy commented, "With WT-1 highly expressed in 20+ cancers, we believe GPS is a platform immunotherapy. At a current market cap of under $30M, success is not yet factored in. Why? In our view, part of the reason is that vaccines in oncology have been overshadowed by CAR-T and checkpoints, which have captured investor attention. GPS is a differentiated vaccine (presented below) that has demonstrated proof of concept; we believe it is poised to emerge as a viable immunotherapy in the IO space and as such, we see upside."

For an analyst ratings summary and ratings history on SELLAS Life Sciences Group click here. For more ratings news on SELLAS Life Sciences Group click here.

Shares of SELLAS Life Sciences Group closed at $4.79 Friday.

You May Also Be Interested In

• Coinbase (COIN) PT Raised to $212 at Cantor Fitzgerald
• Airbnb Inc. (ABNB) PT Raised to $220 at DA Davidson on 'Experiences' Momentum
• AutoZone (AZO) PT Lowered to $3,500; TD Cowen: 'Strong Execution But Not Immune To Industry DIY Headwinds'